当前位置: 首页 >> 检索结果
4201. Triggering of myocardial infarction by cocaine.
作者: M A Mittleman.;D Mintzer.;M Maclure.;G H Tofler.;J B Sherwood.;J E Muller.
来源: Circulation. 1999年99卷21期2737-41页
Cocaine has been implicated as a trigger of acute myocardial infarction in patients with and those without underlying coronary atherosclerosis. However, the magnitude of the increase in risk of acute myocardial infarction immediately after cocaine use remains unknown.
4202. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.
作者: E M Antman.;R P Giugliano.;C M Gibson.;C H McCabe.;P Coussement.;N S Kleiman.;A Vahanian.;A A Adgey.;I Menown.;H J Rupprecht.;R Van der Wieken.;J Ducas.;J Scherer.;K Anderson.;F Van de Werf.;E Braunwald.
来源: Circulation. 1999年99卷21期2720-32页
The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI.
4203. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
ACE inhibitors may not adequately suppress deleterious levels of angiotensin II in patients with heart failure. An angiotensin receptor blocker added to an ACE inhibitor may exert additional beneficial effects.
4204. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition.
作者: U Elkayam.;J V Johnson.;A Shotan.;S Bokhari.;A Solodky.;M Canetti.;O R Wani.;I S Karaalp.
来源: Circulation. 1999年99卷20期2652-7页
Organic nitrates are widely used in the treatment of chronic heart failure (CHF). No information, however, is available regarding their effect in patients already treated with ACE inhibitors.
4205. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.
作者: M L Kukin.;J Kalman.;R H Charney.;D K Levy.;C Buchholz-Varley.;O N Ocampo.;C Eng.
来源: Circulation. 1999年99卷20期2645-51页
With beta-blocker use becoming more prevalent in treating chronic heart failure (CHF), the choice of drugs raises important theoretical and practical questions. Although the second-generation compound metoprolol is beta1-selective, the third-generation compound carvedilol is beta-nonselective, with ancillary pharmacological properties including alpha-blockade and antioxidant effects. A prospective comparison of these 2 agents can address the issue of optimal adrenergic blockade in selecting agents for therapy in CHF.
4206. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.
The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study addressed prognostic factors and the effects of concomitant treatment and glycometabolic control in diabetic patients with myocardial infarction (AMI).
4207. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation.
作者: A M Gillis.;D G Wyse.;S J Connolly.;M Dubuc.;F Philippon.;R Yee.;P Lacombe.;M S Rose.;C D Kerr.
来源: Circulation. 1999年99卷19期2553-8页
This study tested the hypothesis that rate-adaptive atrial pacing would prevent paroxysmal atrial fibrillation (PAF) in patients with frequent PAF in the absence of symptomatic bradycardia.
4208. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy.
作者: C M Matter.;L Mandinov.;P A Kaufmann.;G Vassalli.;Z Jiang.;O M Hess.
来源: Circulation. 1999年99卷18期2396-401页
Previous experimental studies have shown that nitric oxide (NO) modulates cardiac function by an abbreviation of systolic contraction and an enhancement of diastolic relaxation. However, the response to NO donors of patients with severe pressure-overload hypertrophy and diastolic dysfunction is unknown.
4209. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
作者: K W Mahaffey.;R A Harrington.;M L Simoons.;C B Granger.;C Graffagnino.;M J Alberts.;D T Laskowitz.;J M Miller.;M A Sloan.;L G Berdan.;C M MacAulay.;A M Lincoff.;J Deckers.;E J Topol.;R M Califf.
来源: Circulation. 1999年99卷18期2371-7页
The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.
4210. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
作者: I Moussa.;M Oetgen.;G Roubin.;A Colombo.;X Wang.;S Iyer.;R Maida.;M Collins.;E Kreps.;J W Moses.
来源: Circulation. 1999年99卷18期2364-6页
Ticlopidine has been shown to reduce the incidence of stent thrombosis compared with warfarin, but it may cause serious hematological side effects. Clopidogrel, a new thienopyridine derivative, may be a safe alternative to ticlopidine. The aim of this study was to compare the safety and efficacy of clopidogrel and aspirin with those of ticlopidine and aspirin in patients undergoing coronary stent implantation.
4211. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.
作者: F Boutitie.;J P Boissel.;S J Connolly.;A J Camm.;J A Cairns.;D G Julian.;M Gent.;M J Janse.;P Dorian.;G Frangin.
来源: Circulation. 1999年99卷17期2268-75页
Investigations with in vitro and animal models suggest an interaction between amiodarone and beta-blockers. The objective of this work was to explore if an interaction with beta-blocker treatment plays a role in the decrease of cardiac arrhythmic deaths with amiodarone in patients recovered from an acute myocardial infarction.
4212. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
作者: M Quinn.;A Deering.;M Stewart.;D Cox.;B Foley.;D Fitzgerald.
来源: Circulation. 1999年99卷17期2231-8页
Dosing of glycoprotein (GP) IIb/IIIa receptor antagonists is frequently based on the inhibition of platelet aggregation, which may be influenced by the agonist used or concurrent medications. Here we describe a monoclonal antibody-based technique to quantify total and ligand-occupied GPIIb/IIIa receptors.
4213. Beneficial impact of preconditioning during PTCA on creatine kinase release.
Previous studies in humans have indicated that there is less ischemic dysfunction during PTCA when ischemic preconditioning is elicited. However, the clinical relevance of these observations remains unclear. The present study design tests the hypothesis that PTCA performed to elicit the preconditioning response would result in less myocardial necrosis as assessed by postprocedure creatine kinase (CK) levels.
4214. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy.
4215. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
作者: A M Lincoff.;J E Tcheng.;R M Califf.;D J Kereiakes.;T A Kelly.;G C Timmis.;N S Kleiman.;J E Booth.;C Balog.;C F Cabot.;K M Anderson.;H F Weisman.;E J Topol.
来源: Circulation. 1999年99卷15期1951-8页
Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody fragment abciximab was shown in a placebo-controlled randomized trial to reduce the incidence of acute ischemic complications within 30 days among a broad spectrum of patients undergoing percutaneous coronary revascularization. The durability of clinical benefit in this setting has not been established.
4216. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group.
作者: C M Gibson.;S A Murphy.;M J Rizzo.;K A Ryan.;S J Marble.;C H McCabe.;C P Cannon.;F Van de Werf.;E Braunwald.
来源: Circulation. 1999年99卷15期1945-50页
The corrected TIMI frame count (CTFC) is the number of cine frames required for dye to first reach standardized distal coronary landmarks, and it is an objective and quantitative index of coronary blood flow.
4217. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.
Although long-term prostacyclin (PGI2) has been shown to improve hemodynamics, quality of life, and survival in patients with primary pulmonary hypertension, its use in patients with pulmonary hypertension (PHT) and associated congenital heart defects (CHD) has not been evaluated.
4218. Effect of butorphanol tartrate on shock-related discomfort during internal atrial defibrillation.
作者: C Timmermans.;L M Rodriguez.;G M Ayers.;H Lambert.;J L Smeets.;J W Vlaeyen.;A Albert.;H J Wellens.
来源: Circulation. 1999年99卷14期1837-42页
In patients with atrial fibrillation, intracardiac atrial defibrillation causes discomfort. An easily applicable, short-acting analgesic and anxiolytic drug would increase acceptability of this new treatment mode.
4219. Impaired force-frequency relations in patients with hypertensive left ventricular hypertrophy. A possible physiological marker of the transition from physiological to pathological hypertrophy.
作者: M Inagaki.;M Yokota.;H Izawa.;R Ishiki.;K Nagata.;M Iwase.;Y Yamada.;M Koide.;T Sobue.
来源: Circulation. 1999年99卷14期1822-30页
The extent to which force-frequency and relaxation-frequency relations (FFR and RFR, respectively) and exercise-induced adrenergic stimulation affect myocardial inotropic and lusitropic reserves has not been established in patients with left ventricular (LV) hypertrophy (LVH).
4220. Gender differences in survival in advanced heart failure. Insights from the FIRST study.
作者: K F Adams.;C A Sueta.;M Gheorghiade.;C M O'Connor.;T A Schwartz.;G G Koch.;B Uretsky.;K Swedberg.;W McKenna.;J Soler-Soler.;R M Califf.
来源: Circulation. 1999年99卷14期1816-21页
Previous natural history studies in broad populations of heart failure patients have associated female gender with improved survival, particularly in patients with a nonischemic etiology of ventricular dysfunction. This study investigates whether a similar survival advantage for women would be evident among patients with advanced heart failure.
|